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Mounting evidence suggests that imbalances in immune regulation contribute to cell
transformation. Women of African descent are an understudied group at high risk for
developing aggressive breast cancer (BrCa). Therefore, we examined the role of 16 innate
immune single nucleotide polymorphisms (SNPs) in relation to BrCa susceptibility among
174 African-American women in Atlanta, GA, USA. SNPs were examined in germ-line DNA
collected from 102 BrCa patients and 72 women with benign nodules using SNPstream
methodology. Inheritance of the TLR3 rs10025405 GG genotype was associated with an
82% decrease in BrCa risk. In contrast, individuals who possessed at least one IRAK4
rs4251545 T allele had a 1.68- to 4.99-fold increase in the risk of developing BrCa relative
to those with the referent genotype (OR=4.99; 95% CI=1.00, 25.00; p=0.0605). How-
ever, the IRAK4 rs4251545 locus was only significant under the additive genetic model (p
trend=0.0406). In silico predictions suggest IRAK4 rs4251545 SNP falls within a transcrip-
tion enhancer/silencer region of the gene and codes for an Ala428Thr amino acid change.
This missense mutation introduces a potential phosphorylation site in the extreme carboxy
terminus (XCT) of the IRAK4 kinase domain. Preliminary molecular modeling predicts that
this SNP stabilizes two alpha helices within the XCT on the surface of the IRAK4 kinase
domain and increases the size of the groove between them. Our in silico results, com-
bined with previous reports noting the presence of IRAK4 and XCT fragments in mouse
and human serum, suggest the possibility that the XCT subdomain of IRAK4 possesses
biological function. These findings require further evaluation and validation in larger popu-
lations, additional molecular modeling as well as functional studies to explore the role of
IRAK4 and its XCT in cell transformation and innate immunity.
Keywords: breast cancer, innate immunity, single nucleotide polymorphism,TLR3, IRAK4, African-American, XCT
subdomain, extracellular kinase
INTRODUCTION
Breast cancer (BrCa) is the most common cancer morbidity among
women worldwide and is especially prevalent in the US and
other developed countries. Several factors contribute to BrCa risk,
including age, family history of BrCa, personal history of benign
breast disease, late menopause, obesity, high endogenous estrogen
and testosterone levels, adult weight gain, early menarche and null
parity, and BRCA 1/2 mutations. Specific mutations in BRCA1
and BRCA2 are associated with a genetic predisposition to BrCa.
However, these mutations account for only 5–10% of the reported
BrCa cases (1). Exploring the contribution of other genetic fac-
tors associated with BrCa is an active area of research (2). In
Abbreviations: BrCa, breast cancer; CHARMM22, Chemistry at HARvard Macro-
molecular Mechanics 22; CI, confidence interval; IRAK4, interleukin-1 receptor-
associated kinase 4 gene; IRAK4, interleukin-1 receptor-associated kinase 4 protein;
NAMD, not (just) another molecular dynamics simulation software; OR, odds ratio;
SNP, single nucleotide polymorphism; TIP3, 3-site rigid water model; TLR, toll-like
receptor; XCT, extreme carboxy terminus.
fact, compelling evidence has emerged that suggests genetic anom-
alies in inflammatory and immune response pathways may lead to
cellular transformation and contribute to BrCa pathogenesis (3, 4).
Innate immune capabilities enable most tissues, including
breast epithelia, to mount a first response to infection through
several surface and intracellular membrane receptors (5). Best
characterized among these are the Toll-like receptors (TLRs) that
recognize pathogens, dietary or environmental toxins, or endoge-
nous biomolecules that possess specific pathogen-associated mol-
ecular patterns (PAMPs) or damage-associated molecular patterns
(DAMPs). TLRs are triggered as homo- or hetero-dimers and
complex with adaptor molecules that recruit regulatory kinases to
initiate downstream cellular responses, as summarized in Figure 1.
Among these regulatory kinases, IL-1 receptor-associated kinase 4
(IRAK4) is widely employed, and transduces signals from TLRs 1
through 10.
Recent evidence links TLRs and their signaling pathways with
tumor progression (6–9). Enhanced TLR expression at the cell
surface and in endosomes has been observed in several human
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FIGURE 1 | Signal transduction pathways involvingTLR3 and IRAK4.
Surface membrane Toll-like receptors (TLRs, in red) such as TLR1, 2, and 4
respond to specific extracellular pathogen-associated molecular patterns
(PAMPs, in gray), including Gram-positive bacteria (recognized by TLR2 homo-
or hetero-dimers with TLR1/TLR6/TLR10) and lipopolysaccharide (LPS,
recognized by TLR4 homo- or hetero-dimers with TLR2 or TLR1/TLR6/TLR10)
to initiate inflammatory and/or apoptotic signaling pathways. Endosomal TLRs
such as TLR4 (green) and TLR3 (yellow) bind pathogenic fragments, initiating
pro-inflammatory responses, extrinsic caspase-induced apoptosis, and/or
expression of interferon (IFN) regulatory transcription factors [e.g., interferon
regulatory factor 3 (IRF3), light green] and production of type I interferon.
Interleukin-1 receptor-associated kinase 4 (IRAK4, in yellow) mediates
signaling in TLR pathways by responding to myeloid differentiation primary
response gene 88 (MyD88, dark orange) dependent signals on the cell
surface and Toll-interleukin-1 receptor (TIR)-domain-containing
adapter-inducing interferon-β (TRIF, in light blue) dependent signals in
endosomes. Engagement of IRAK4 with these sorting receptors stimulates
autophosphorylation (black “P”) followed by phosphorylation of IRAK1 and/or
IRAK2, tumor necrosis factor receptor-associated factor 6 (TRAF6) activation
and a wide variety of downstream regulatory pathways via such message
integrators as nuclear factor kappa beta (NFkB) and mitogen-activated protein
(MAP) kinases. TLR3 (in yellow) recognition of dsRNA (SS) initiates both
TRAF6-dependent (in purple) stimulation of NFkB to generate a
pro-inflammatory response and TRAF6–independent stimulation of interferon
(IFN) production and extrinsic caspase-driven apoptosis; IRAK4 participates in
both TRAF6-dependent and -independent TLR3 responses.
cancers, including BrCa (10, 11). Total and surface expression of
TLR2 are both enhanced in the highly metastatic MDA-MB-231
human BrCa cell line relative to the less aggressive MDA-MB-468
or untransformed MCF10A cell lines (12). Further, bacterial pep-
tidoglycan stimulation of TLR2 promotes BrCa invasiveness (12).
Consistent with these results, TLR4 knockdown in MDA-MB-231
cells inhibits cell proliferation and inflammatory cytokine secre-
tion (13). Conversely, treatment of MCF7 human BrCa cells with
agonists to TLR3 and TLR7 (both located in intracellular endo-
somes) inhibits BrCa cell growth that is reversible by treatment
with the autophagy inhibitor 3-methyladenine (14). Similarly,
activation of TLR5 by flagellin inhibits the growth of MCF7 and
MDA-MB-468 BrCa cell lines (15) and activation of endosomal
TLR9 with agonist oligo(CpG) inhibits estrogen-induced growth
of MCF7 cells (16). While the precise mechanisms are poorly
understood, these findings suggest that anomalies in TLR signaling
pathways influence BrCa progression.
Consistent with this, TLR-related sequence variants have been
implicated in BrCa susceptibility. Only a few population-based
studies have detected single nucleotide polymorphisms (SNPs)
in genes related to TLR signaling that alter BrCa risk. Among
Korean women, a modest increase in BrCa risk (OR= 1.63; 95%
CI= 1.14, 2.34) was linked with possession of one or more of
the IRAK3 rs1732877 minor alleles (17). Similarly, presence of the
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minor variant of the non-synonymous TLR4 rs4986790 A/G SNP,
in which aspartic acid 299 is replaced by glycine, was associated
with a modest increase in BrCa risk (OR= 1.81; 95% CI= 1.23,
2.66) in a Greek cohort (18). Finally, inheritance of the homozy-
gous minor variant of the TLR1/TLR6/TLR10 rs7696175 locus
(situated in proximity to all three TLR promoters) was associ-
ated with a large fourfold increase in BrCa risk (OR= 4.11; 95%
CI= 1.28, 13.24) among African-American women as opposed to
little or no risk among women of European ancestry (OR= 1.20;
95% CI= 0.93, 1.53) (19). Only the last of these studies addressed
BrCa risk among women of African descent, despite the fact that
this sub-group suffers disproportionately from more aggressive
forms of BrCa (20, 21) and is underrepresented in BrCa research
efforts (22).
The study of the biological/genetic factors that contribute to
disparities in BrCa risk and severity among women of various
races is a nascent science, and to date has focused most heavily
on differences in hormone receptor expression (2). Barnholtz-
Sloan et al. (19) explored a large panel of SNPs from genes with
a variety of functions that had been previously reported as BrCa
susceptibility genes in genome wide association (GWAS) studies
(19). Notably, the minor allele frequency of the TLR1/TLR6/TLR10
rs7696175 allele in the Barnholtz-Sloan study is highly disparate
between women of African and European descent (3 and 44%,
respectively). Consequently, we selected additional TLR-pathway
associated SNPs, in part, based on significant disparities in minor
allele frequency (≥10% difference) between individuals of African
and European descent (Table 1). In the current study, we eval-
uated 16 TLR-associated SNPs in relation to BrCa among 174
African-American female participants (102 BrCa cases, 72 benign
controls).
MATERIALS AND METHODS
STUDY POPULATION AND TUMOR CHARACTERIZATION
Study participants, including 102 BrCa cases and 72 benign con-
trols were enrolled from Grady Memorial Hospital and Emory
Midtown Hospital in Atlanta, GA, USA. All participants self-
identified as African-Americans and provided written informed
consent for participation in genetic analysis studies under proto-
col #20417 approved by Emory University’s Institutional Review
Board. Socioeconomic status, nutrition, environmental exposure,
and other confounding factors were not addressed. Tumor size
was measured and tumor stage and invasiveness/morphology
were determined according to standard histopathological defin-
itions. Estrogen (ER) and progesterone receptor (PR) and Her-
2 neu expression were determined by immunohistochemistry
staining (23).
CRITERIA FOR TLR SIGNALING GENE AND SNP SELECTION
Toll-like receptor-associated genes and SNPs were selected using
one or more of the following criteria: (1) epidemiological or
molecular biological evidence from published reports indicating
a relationship between the SNP/gene with cancer or inflamma-
tory/immune response related diseases (Figure 1); (2) commonly
studied loci; (3) marked disparities in genotype frequency com-
paring women of African descent to their Caucasian counter-
parts (i.e., ±10% change) (Table 1); (4) evidence demonstrating
a link with alterations in mRNA expression/stability or protein
expression/structure or function using in silico tools or published
reports1; and (5) a minor allele frequency ≥1% reported in the
National Center for Biotechnology Information (NCBI) Entrez
SNP (24)2. The current study focused on 16 SNPs detected in
10 TLR genes as well as downstream markers associated with TLR
mediated signaling pathways (i.e., TLR1-4, CD14, IRAK2&4, IRF3,
TICAM1, TOLLIP), as described in Table 1.
SNPSTREAM GENOTYPING
Sixteen candidate SNPs among African-American subjects were
genotyped using the GenomeLab™ SNPstream® Genotyping Sys-
tem (Beckman Coulter, Brea, CA, USA) within the Center for
Medical Genomics at Emory University. SNPstream executes high-
throughput multiplex genotyping using single-base fluorescent
primer extension. Primers were designed using autoprimer tools3.
Following primer design, allelic discrimination was facilitated, in
part, by PCR amplification of 100 base pairs flanking each SNP
using 384-well PCR plates. GenomeLabSNPstream Genotyping
System Software Suite v2.3 was used for image processing and
genotype base calling.
STATISTICAL ANALYSIS
Logistic regression (LR) analysis was used to evaluate innate
immunity associated SNPs among African-Americans in rela-
tion to BrCa risk. To assess whether individuals possessing innate
immune sequence variants influence the risk of developing BrCa,
we tested for significant differences in the distribution of homozy-
gous major, heterozygous, or homozygous minor genotypes
between cases and controls using the chi-square test of homogene-
ity. The associations between BrCa risk and selected polymorphic
genes, expressed as odds ratios (ORs) and corresponding 95%
confidence intervals (CIs), were estimated using unconditional
multivariate LR models. Risk estimates were adjusted for age. LR
analyses for genetic variants and BrCa development were con-
ducted using the major/common genotype as the reference group.
All chi-square and LR analyses were conducted using SAS 9.1.3
(SAS Institute, Cary, NC, USA). Statistical significance required a
P-value <0.05.
MOLECULAR MODELING
Molecular dynamics (MD) simulations were performed to exam-
ine the effect of the IRAK4 rs4251545 Ala428Thr variant on
enzyme structure, as described previously (25), as described pre-
viously. Briefly, simulations were performed with NAMD parallel,
object-oriented high-performance software (ver. 2.6b2 for Linux-
Power-MPI). CHARMM22 force field parameters were used for
the protein along with the three-site TIP3 rigid water model. Ini-
tial coordinates of IRAK4 were obtained from the x-ray structure
of the human IRAK4 kinase domain from amino acids 160–460
(PDB code: 2OIB) (26). A model of the IRAK4 rs4251545 variant
was generated by replacing Ala428 in IRAK4 with a Thr residue.
After immersion of IRAK4 in a rectangular cell of water molecules
1http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm
2www.ncbi.nlm.nih.gov
3http://www.autoprimer.com
www.frontiersin.org October 2013 | Volume 4 | Article 338 | 3
Yeyeodu et al. IRAK4, TLR3, and BrCa risk
Table 1 | Prevalence of selected innate immunity sequence variants and their functional consequence.
dbSNP ID Gene NT
change
MAF
AA (%)
Major/
major
genotype
n (%) AA
Major/
minor
genotype
n (%) AA
Minor/
minor
genotype
n (%) AA
MAF
Cau
(%)
Major/
major
genotype
n (%) Cau
Major/
minor
genotype
n (%) Cau
Minor/
minor
genotype
n (%) Cau
P -valuea
AA vs.
Cau
rs10025405 TLR3 A>G G=31.6 24 (49.0) 19 (38.8) 6 (12.2) G=42.0 39 (34.5) 53 (46.9) 21 (18.6) 0.205
rs10759930 TLR4 C>T T=8.7 19 (82.6) 4 (17.4) 0 (0.0) T=41.7 7 (29.2) 14 (58.3) 3 (12.5) 0.0006
rs11672931 TICAM1
(aka TRIF)
G=23.8 12 (57.1) 8 (38.1) 1 (4.8) G=27.3 13 (59.1) 6 (27.3) 3 (13.6) 0.606
rs242724 IRAK2 A>C C=22.7 6 (54.5) 5 (45.5) 0 (0.0) C=31.0 56 (49.6) 44 (38.9) 13 (11.5) 0.735
rs2569188 CD14 A>G G=39.8;
A=60.2
18 (36.7) 23 (46.9) 8 (16.3) A=49.1 24 (21.4) 62 (55.4) 26 (23.2) 0.118
rs4251545 IRAK4 G>A A=32.6 11 (47.8) 9 (39.1) 3 (13.0) A=10.4 19 (79.2) 5 (20.8) 0 (0.0) 0.036
rs4684672 IRAK2 G>A A=22.7 14 (63.6) 6 (27.3) 2 (9.1) A=39.5 7 (36.8) 9 (47.4) 3 (15.8) 0.224
rs4696480 TLR2 T>A A=39.6 8 (33.3) 13 (54.2) 3 (12.5) A=46.8 8 (25.8) 17 (54.8) 6 (19.4) 0.759
rs4833095 TLR1 C>T T=34.8;
C=65.2
11 (47.8) 8 (34.8) 4 (17.4) C=20.8 15 (62.5) 8 (33.3) 9 (4.2) 0.577
rs4986790 TLR4 A>G G=3.3 20 (83.3) 4 (16.7) 0 (0.0) G=4.4 29 (93.5) 2 (6.5) 0 (0.0) 0.387
rs5743899 TOLLIP A>G G=34.8 9 (39.1) 12 (52.2) 2 (8.7) G=17.9 75 (67.0) 34 (30.4) 3 (2.7) 0.019
rs6442161 IRAK2 C>T T=21.9 30 (62.5) 15 (31.2) 3 (6.2) T=42.5 41 (36.3) 48 (42.5) 24 (21.2) 0.00400
rs7251 IRF3 C>G G=25.0;
C=75.0
14 (58.3) 8 (33.3) 2 (8.4) C=37.1 21 (36.2) 31 (53.4) 6 (10.3) 0.205
rs7045953 TLR4 A>G G=17.4 15 (65.2) 8 (34.8) 0 (0.0) G=14.6 80 (70.8) 33 (29.2) 0 (0.0) 0.623
rs7657186 TLR3 G>A A=25.0 13 (54.2) 10 (41.7) 1 (4.2) A=24.5 18 (60.0) 9 (30.0) 3 (10.0) 0.578
rs913930 TLR4 A>G G=28.3 14 (60.9) 5 (21.7) 4 (17.4) G=38.1 48 (42.5) 44 (38.9) 21 (18.6) 0.198
MAF, minor allele frequency; AA, African-American/African Ancestry; Cau, Caucasian;
aThe Fisher’s Exact test or chi-square test of homogeneity was used to compare the genotype frequencies from women of African and European descent using data
from NCBI.
to produce a periodic box of dimension 93 Å× 89 Å× 96 Å, the
variant enzyme system was subjected to 2,500 steps of minimiza-
tion. The minimized structure was then simulated for 5 ns in a
constant temperature and pressure ensemble. The temperature
was maintained at 310°K through the use of Langevin dynamics
with a damping coefficient of 1/ps. The pressure was maintained
at one ATM by using the Nosé–Hoover method. The van der Waals
interactions were switched at 10 Å and zeroed smoothly at 12 Å.
Electrostatic interactions were monitored using the Particle Mesh
Ewald (PME) method (27). A pair list for calculating the van der
Waals and electrostatic interactions was set to 13.5 Å and updated
every ten steps. The timestep size for integration of each step of
the simulation was 1 fs. The resulting variant was compared with
the wild-type enzyme structure.
RESULTS
CHARACTERIZATION OF PATIENTS AND THEIR TUMORS
The patient and tumor characteristics of our study participants
are summarized in Table 2. For this pilot study based in Atlanta,
GA, we enrolled 174 African-American women who had been
diagnosed with BrCa or who possessed benign nodules (con-
trol). At enrollment, BrCa patients were approximately 10 years
older than women with benign disease (<0.0001); about 66% of
the cases were diagnosed after age 50. The majority of the breast
tumors were characteristic of earlier stages (Stage 0–II) of disease
(91.8%) with invasive pathologies (64.7%), namely invasive lobu-
lar or uninvasive ductal carcinomas. Further, more than half of the
cases lacked expression of estrogen receptor (31.6%), PR (39.8%),
or Her-2 neu (87.3%), resulting in 29.6 and 22.1% double or triple
negative breast tumors, respectively.
PREVALENCE OF MINOR ALLELES/GENOTYPE FREQUENCY
The prevalence of the 16 TLR variants was fairly common among
the women of African descent in our study, based on a minor allele
frequency ≥5%. With the exception of the functional Ala299Gly
TLR4 rs4986790 variant, the minor allele frequencies among con-
trols in our study set ranged between 8.7 and 39.8%, with a median
of 22.0%. Approximately 16% of the women possessed one copy of
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Table 2 | Patient and tumor characteristics.
Characteristics Cases
n (%)
Controls
n (%)
p-Value
Median age at enrollment (range) 57 (24–89) 47 (18–78) <0.0001
Age at enrollment (years)
>70 20 (19.6) 6 (8.3) 0.0002
61–70 17 (16.7) 5 (6.9)
51–60 35 (34.3) 20 (27.8)
41–50 23 (22.5) 19 (26.4)
≤40 7 (6.9) 22 (30.6)
Age at diagnosis (years)
>70 7 (6.9)
61–70 23 (22.5)
51–60 37 (36.3)
41–50 16 (15.7)
≤40 19 (18.6)
Tumor stage
0 35 (35.7)
I 30 (30.6)
II 25 (25.5)
III 3 (3.1)
IV 5 (5.1)
Not determined 4 (3.9)
Tumor size (cm)
<2 53 (60.9)
≥2 34 (39.1)
Not determined 15 (14.7)
Nodal status
Negative 45 (68.2)
Positive 21 (31.8)
Not determined 36 (35.3)
Pathology
Non-invasive (DCIS, LCIS) 36 (35.3)
Invasive (IDC, ILC) 66 (64.7)
Not determined 0 (0.0)
Estrogen receptor (ER)
Positive 67 (68.4)
Negative 31 (31.6)
Not determined 4 (3.9)
Progesterone receptor (PR)
Positive 59 (60.2)
Negative 39 (39.8)
Not determined 4 (3.9)
Her-2 neu
Positive 9 (12.7)
Negative 62 (87.3)
Not determined 31 (30.4)
Triple negative BrCaa
No 74 (77.9)
Yes 21 (22.1)
Not determined 7 (6.9)
Double negative BrCab
No 69 (70.4)
Yes 29 (29.6)
Not determined 4 (3.9)
(Continued)
Characteristics Cases
n (%)
Controls
n (%)
p-Value
Surgery status
No surgery(biopsy only) 3 (2.9)
Lumpectomy 33 (32.4)
Partial mastectomy 25 (24.5)
Total mastectomy 34 (33.3)
Modified radical mastectomy 6 (5.9)
Unknown 1 (1.0)
aER-, PR-, Her2-
bER-, PR-
the TLR4 rs4986790 A/G genotype, with a minor allele frequency
of 3.3%. For 15 out of 16 innate immunity SNPs, there were
no significant departures in the observed genotype frequencies
among controls when compared with expected frequencies under
the Hardy–Weinberg Equilibrium (HWE) [p≥ 0.4833]. Moreover,
the prevalence of the genotypes among controls was comparable
to those reported for women of African descent in NCBI SNP
Entrez (p≥ 0.056) (24). Only the TICAM1 rs11672931 variant
deviated from HWE (p= 0.0027), despite the fact that its allele
(27.3%) and genotype frequency among our study participants
corroborated with NCBI values (24).
RELATIONSHIP BETWEEN TLR-ASSOCIATED SEQUENCE VARIANTS
AND BREAST CANCER RISK
SNPstream analysis of 16 innate immunity SNPs among African-
American women with BrCa (n= 102) and benign disease
(n= 72) identified 4 loci whose genotype frequencies were altered
with respect to BrCa risk (Table 3). In the unadjusted mod-
els, three of these were associated with a decrease in BrCa risk.
Possession of one or more minor TLR2 rs4696480 A, TLR3
rs10025403 G, and IRAK2 rs6442161 T alleles was associated
with a 45–79% reduction in the risk of developing BrCa. Among
these three loci, statistical significance was observed only for
the TLR3 rs10025403 marker under the unadjusted and/or age-
adjusted dominant (OR= 0.18, 95% CI= 0.05, 0.70); p= 0.0123),
recessive (OR= 0.20, 95% CI= 0.06, 0.75; p-value= 0.0143),
and additive (unadjusted p-value for trend= 0.0337) genetic
models.
On the other hand, inheritance of two copies of the IRAK4
rs4251545 TT genotype resulted in a fivefold increase in BrCa sus-
ceptibility relative to those with the referent genotype (OR= 4.99;
95% CI= 1.00, 25.00; p= 0.0605); however, the findings were not
statistically significant. Notably, under the additive genetic model,
we observed a significant “dose-response” between the number of
alleles in the genetic model (i.e., 0, 1, 2) and the risk estimates
(p-value for trend= 0.0406) for this SNP.
FUNCTIONAL CONSEQUENCES OF TLR3 rs10025405 AND IRAK4
rs4251545
Inheritance of the homozygous minor TLR3 rs10025405 G allele
was associated with reduced BrCa risk. The location of this SNP
in the 3′ flanking region of the TLR3 gene may alter mRNA
expression or processing with resulting downstream effects on
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Table 3 | Innate immune SNPs associated with BrCa risk amongAfrican-American women.
Genes dbSNP ID location
predicted function
Genotype Cases
n (%)
Controls
n (%)
NCBI
AA
OR (95% CI) Adj OR (95% CI) p-Value p-Value
for trend
TLR2 rs4696480 TT 47 (46.1) 23 (31.9) 0.33 1.00 (reference) 1.00 (reference) 0.1357 0.1959
Intron 1 TA 37 (36.3) 36 (50.0) 0.54 0.50 (0.26, 0.99) 0.56 (0.27, 1.18) 0.0469
1685bp from 5’ AA 18 (17.6) 13 (18.1) 0.13 0.68 (0.28, 1.62) 0.53 (0.21, 1.34) 0.3808
≥1 A allele 55 (53.9) 49 (68.1) 0.67 0.55 (0.29, 1.03) 0.55 (0.28, 1.09) 0.0624
AA vs (TT +TA) 0.97 (0.44, 2.14) 0.70 (0.30, 1.65) 0.9446
TLR3 rs10025405 AA 54 (53.0) 31 (43.1) 0.66 1.00 (reference) 1.00 (reference) 0.0276 0.0337
3’ near gene AG 44 (43.1) 30 (41.6) 0.31 0.84 (0.44, 1.59) 0.80 (0.40, 1.62) 0.5987
GG 4 (3.9) 11 (15.3) 0.04 0.21 (0.06, 0.71) 0.18 (0.05, 0.70) 0.0123
≥1 G allele 48 (47.0) 41 (56.9) 0.35 0.67 (0.37, 1.23) 0.64 (0.33, 1.24) 0.1997
GG vs (AA + AG) 0.23 (0.07, 0.74) 0.20 (0.06, 0.75) 0.0143
IRAK2 rs6442161 CC 56 (54.9) 33 (45.8) 1.00 (reference) 1.00 (reference) 0.1058 0.0721
Intron 1 CT 40 (39.2) 28 (38.9) 0.84 (0.44, 1.61) 1.05 (0.52, 2.13) 0.6018
TT 6 (5.9) 11 (15.3) 0.32 (0.11, 0.95) 0.32 (0.10, 1.11) 0.0401
>1 T allele 46 (45.1) 39 (54.2) 0.70 (0.38, 1.27) 0.85 (0.44, 1.64) 0.2393
TT vs (CC + CT) 0.35 (0.12, 0.99) 0.32 (0.10, 1.05) 0.0469
IRAK4 rs4251545 CC 50 (49.0) 44 (62.0) 0.46 1.00 (reference) 1.00 (reference) 0.0991 0.0406
Exon CT 42 (41.2) 25 (35.2) 0.39 1.51 (0.80, 2.86) 1.68 (0.83, 3.40) 0.2042
Splicing TT 10 (9.8) 2 (2.8) 0.15 4.50 (0.94, 21.6) 4.99 (1.00, 25.00) 0.0605
(ESE, ESS) ≥1 T allele 52 (51.0) 27 (38.0) 0.54 1.70 (0.92, 3.14) 1.90 (0.97, 3.75) 0.0936
Ala428Thr TT vs (CT +TT) 3.75 (0.80, 17.66) 3.96 (0.81, 19.3) 0.0947
AA, African-American/African ancestry; OR, unadjusted odds ratio; Adj OR, adjusted odds ratio; CI, confidence interval.
microbial nucleic acid recognition, intracellular signaling, and/or
endosomal/lysosomal processing and degradation.
The IRAK4 rs4251545 SNP codes for an Ala to Thr amino acid
change at position 428. This non-synonymous mutation intro-
duces a potential Ser/Thr kinase target and presents a bulkier and
more polar residue. Further, the IRAK4 rs4251545 locus occurs
in an enhancer/silencer region of the gene, raising the additional
possibility that this SNP may influence IRAK4 transcription levels.
IMPACT OF IRAK4 rs4251545 ON SUBDOMAIN CONFORMATION
In order to investigate the biochemical impact of the IRAK4
rs4251545 locus on the aforementioned disease states, we first
noted the location of the missense mutation coded by this SNP in
the context of the IRAK4 protein. The most definitive structural
data that includes amino acid 428 (coded by IRAK4 rs4251545)
is derived from x-ray diffraction of tetrameric crystals of the
inhibitor-bound IRAK4 kinase domain (amino acid residues 160–
460) (26). Figure 2 illustrates the IRAK4 kinase domain monomer
in the context of the tetrameric crystal; amino acid 428 is repre-
sented in mauve, key residues of the activation loop are coded
red, and key residues of the active binding site pocket are keyed
green. We observed that amino acid 428 is located near the cen-
ter of the penultimate αI helix on the surface of the truncated
protein and faces the adjacent and almost parallel carboxy ter-
minal α helix, αJ. We refer to the subdomain in which the IRAK4
rs4251545 polymorphism resides as the extreme carboxy terminus
(XCT). Specifically, the XCT, depicted in yellow within Figure 2,
encompasses amino acid residues from approximately 418–460
and is comprised of the two carboxy terminal α helices (αI and αJ)
and a putative 3/10 helix (with fewer residues per turn than the
traditional α helix).
We performed MD simulations of the Ala428Thr variant to
examine the impact of the IRAK4 rs4251545 coded missense muta-
tion on local XCT conformation at the surface of the IRAK4
kinase domain. Superposition of the wild-type Ala 428 and vari-
ant Thr 428 structures with respect to the backbone atoms of
αI and the underlying αG and αE helices in dark blue, deep to
αI and αJ, respectively, suggested differences in inter- and intra-
helical dynamics between wild-type IRAK4 rs4251545 Ala and
variant Thr alleles. Specifically, the Thr 428 variant enhances the
H-bonding capabilities of αI and αJ, stabilizing them both. Replac-
ing Thr for Ala also expands the inter-helical distance between αI
and αJ, increasing the size of the groove between them.
DISCUSSION
Dysregulation of and genetic alterations in inflammation and
immune response pathways have been linked with cancer sus-
ceptibility (6–9, 28). Although African-American women suffer
disproportionately from more deadly forms of BrCa, only one
study has explored the involvement of a single TLR-associated
SNP (TLR1/TLR6/TLR10 rs7696175) in relation to BrCa among
this high risk sub-group (19). To explore whether other genetic
susceptibilities in the TLR-pathway play a role in BrCa among
African-American women, we examined 16 SNPs from 10 TLR-
pathway genes in a pilot case-control study. We found that the
TLR3 rs10025405 and IRAK4 rs4251545 loci under the additive
genetic models were associated with significant alterations in BrCa
risk among African-American women.
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FIGURE 2 | Structural features of the IRAK4 kinase domain. The
Ala428Thr (mauve) non-synonymous SNP is located on αI, the penultimate
alpha helix, facing the carboxy terminal αJ as part of the putative extreme
carboxy terminal (XCT) subdomain (yellow). Preliminary molecular dynamics
simulations superpositioned backbone atoms of αI (yellow), αG (blue), and
αE (blue) to evaluate local structural changes introduced by replacing Ala428
with Thr. The location of key residues in known functional domains,
including Thr342, Thr345, and S346 of the activation loop (red) and amino
acids 262 through 269 in the ATP binding domain (green) are also indicated.
TLR3
Inheritance of the homozygous minor TLR3 rs10025405 G allele
was associated with a fivefold reduction in BrCa risk. While
the location of this SNP in the 3′ flanking region may alter
mRNA expression/processing or gene product function (e.g.,
anti-tumor response, cell death), to our knowledge there are
no published reports on the relationship between this TLR3
SNP and human disease. However, there is direct and indi-
rect pre-clinical as well as clinical evidence that TLR3 impacts
breast tumor viability and/or behavior using TLR3-specific ago-
nists, namely polyadenylic-polyuridylic acid [poly(A:U)] and
polyinosinic-polycytidylic [poly(I:C)]. These agents are synthetic
double-stranded RNA molecules that have been widely used as
potent adjuvants in cancer immunotherapy, based on their ability
to promote antigen-specific Th1-anti-tumor immune responses
and boost antibody production when administered with anti-
gen in mice (29–31). Salaun et al. (32) found that poly(A:U)
treatment reduced breast tumor burden in immune compro-
mised SCID/NOD mice, suggesting that the anti-tumor effects
of poly(A:U) is attributed to TLR3 expressed by breast tumors
rather than immune cells. The use of poly(A:U) increased BrCa
patient survival and reduced tumor metastasis in two random-
ized clinical trials (33, 34). In addition, poly(A:U) specifically
reduced metastatic relapse among patients who possessed TLR3
positive tumors in a recent European clinical trial (32). Consistent
with this, treatment of three out of four human BrCa lines with
poly(I:C) induced apoptosis in vitro (35), and poly(A:U) inhibited
HCC1806 BrCa tumor growth in vitro and in vivo (32).
Given that tumor-expressed TLR3 appears to promote apop-
tosis in transformed breast epithelia, it is reasonable to speculate
that the TLR3 rs10025405 variant (protective among the African-
American women in our pilot study) alters TLR3 expression.
In addition, the mechanism of TLR3-triggered BrCa apoptosis
also requires downstream signaling via TRIF/TRAM1 (MyD88-
independent) and IRAK4 in Cama-1 human BrCa cells (35–37).
Interestingly, in these cells type I IFN enhanced but could not initi-
ate apoptosis (35). Thus, even if the TLR3 rs10025405 minor vari-
ant alters TLR3 expression, other factors, such as those that influ-
ence TLR3 regulation, localization, and/or signaling pathways, are
also likely to impact TLR3-triggered BrCa apoptosis.
IRAK4
This report also finds that the IRAK4 rs4251545 variant in the XCT
subdomain of IRAK4 (amino acids 418–460) is associated with a
fivefold increase in BrCa risk among African-American women.
While the minor variant of this SNP has been associated with
Gram-positive bacterial infections (38), this report is the first to
correlate this or any IRAK4 polymorphism with BrCa risk. IRAK4
rs4251545 simultaneously impacts a putative enhancer/silencer
site (and subsequent IRAK4 expression levels) and alters the amino
acid sequence (and possibly IRAK4 structure, phosphorylation
state, kinase activity, and/or protein–protein interactions). We can
envision a variety of scenarios in which the IRAK4 rs4251545
minor variant might promote BrCa risk by altering the expres-
sion or phosphorylation state of IRAK4 or its interaction with
upstream adaptors (like MyD88) and/or downstream kinases (like
IRAK1 and IRAK2) and E3 ubiquitin ligases (like TRAF6). Given
our data on TLR3, it is also possible IRAK4 rs4251545 impairs
TLR3-mediated apoptotic signaling and aids the survival of trans-
formed breast epithelia. IRAK4 was first observed in the serum
of both normal individuals and those with renal carcinoma (39).
Further, host peptides corresponding to the IRAK4 XCT (aa 417-
441) were isolated from the serum of MCF7 BrCa xenografted
mice (40). These findings prompt intriguing questions about the
biological impact of IRAK4 trafficking and processing and the role
of the XCT fragment.
The association of IRAK4 with BrCa risk in African-American
women is not unexpected. Given that IRAK4 is a common medi-
ator of TLR signaling from the cell surface and from endosomes
(Figure 1), the fact that all TLRs except TLR8 have been shown
to influence BrCa progression (9) implicates IRAK4 as an accom-
plice. Figure 1 illustrates representative signaling pathways from
surface (TLR2 and TLR4) and endosomal (TLR3 and TLR4)
TLRs [reviewed in Ref. (41)] that converge at IRAK4. It is well-
known that IRAK4 is activated by upstream signaling adaptor
MyD88 docking via their shared death domains and complexes
with IRAK1 to activate downstream E3 ubiquitin ligase TRAF6.
However, it should be noted that TLR-pathway linked IRAK4
responds to both MyD88-dependent and -independent upstream
signals and prompts both TRAF6-dependent and -independent
downstream signaling (35,42). As shown in Figure 1, IRAK4 medi-
ated signaling results in a wide range of cancer-related cellular
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responses, including: imbalances in cell survival/cell death; pro-
duction of pro-inflammatory cytokines and chemokines; expres-
sion of interferons and interferon-inducible genes; and release of
matrix metalloproteinases that degrade extracellular matrix and
facilitate cell migration/metastasis.
STRENGTHS, LIMITATIONS AND FUTURE DIRECTIONS
This report is only the second of its kind to describe the impact of
innate immunity sequence variants on BrCa risk among African-
American women. Under the additive genetic model, we observed
significant alterations in the risk estimates among carriers of the
TLR3 rs10025405 and IRAK4 rs4251545 variant alleles, despite
the use of individuals with benign disease as controls. However, if
disease-free individuals had served as controls, the observed risk
estimates for the TLR3 and IRAK4 loci would have been even
more extreme, since disease-free individuals would be expected
to have a smaller tendency to develop BrCa than individuals with
benign nodules. In other words, the difference in risk between
benign controls and BrCa patients is smaller than the difference
in risk between disease-free controls and BrCa patients. While the
risk estimates were not adjusted for population admixture, which
is a common issue among African-Americans, several genetic epi-
demiology studies indicate that adjustment for population stratifi-
cation only results in a±0.02 change in the risk estimates relative
to unadjusted models (28, 43–47). Despite the large differences
in age between cases and controls, we did not observe signifi-
cant variations in the risk estimates comparing age-adjusted and
unadjusted risk estimates.
A variety of factors may confound the relationship between
variant innate immunity markers and BrCa. In order for a fac-
tor to serve as a confounder, it must be related to BrCa risk
and the expression or function of the innate immunity mark-
ers. It is common knowledge that the risk of developing BrCa
increases with long-term exposure to estrogen due to late age at
menopause, late age at first birth, null parity, overweight/obesity,
use of oral contraceptives, and use of hormone replacement ther-
apy. In addition, there are limited published reports that suggest
exposure to estrogen may alter the production of inflammatory
mediators and cytokines via activation of TLR3 and TLR4 (48,
49). Consequently, the aforementioned reproductive/weight risk
factors may in fact alter the inflammatory response activities of
TLR3 and IRAK4. Unfortunately, we failed to adjust our risk esti-
mates for these two factors and did not acquire this information
from study participants. However, we have considered how our
risk estimates may have varied if they had been adjusted for the
aforementioned potential confounders. Following adjustment for
surrogates of long-term estrogen exposure, we would predict an
increase in BrCa risk estimates for the TLR3 and IRAK4 loci
when compared to unadjusted models, based on the observa-
tion that long-term estrogen exposure enhances the production
of inflammatory mediators in response to TLR4 (and down-
stream IRAK4) activation. Specifically, chronic estrogen expo-
sure promotes TLR4-induced pro-inflammatory mediator pro-
duction (IL-1-β, IL6, TNF-α) in macrophages in vivo (48). In con-
trast, short-term estrogen exposure elicits an anti-inflammatory
response via TLR3, suggesting a corresponding decrease in BrCa
risk (49). Interestingly, short-term exposure to estrogen (i.e., 17
β-estradiol) does not influence TLR3 mRNA/protein expression
in endometrial cell lines, but modulates TLR3 function by sup-
pressing TLR3-ligand induced cytokine/chemokine production
(49). Clearly, additional studies are needed to address the impor-
tant question of whether long-term estrogen exposure influences
TLR3 or IRAK4 expression or function in in vitro and in vivo BrCa
models.
Due to our limited sample size, we did not have ample sta-
tistical power to assess whether the risk of developing BrCa
would vary according to disease severity (i.e., high tumor stage,
tumor size ≥2 cm, invasive pathology, and triple negative BrCa).
In an exploratory analysis of the current study, innate immu-
nity sequence variants [IRAK2 (rs242724, rs6442161), IRAK4
rs4251545), OAS1 rs10774671, CD14 rs2569188, and TLR4
(rs913930, rs7045953)] were significantly related to disease aggres-
siveness. For instance, IRAK4 rs4251545 was associated with a
2.56-fold increase in invasive disease (OR= 2.56; 95% CI= 1.1–
5.91); whereas, inheritance of the IRAK2 rs242724 minor alleles
were linked to non-aggressive disease (i.e., tumor size <2 cm,
ER+ /PR+ /Her-2 neu+ status).
From a statistical point of view, our results can only be con-
sidered suggestive and will require additional evaluation and
validation in larger multi-center studies. Nevertheless, the poten-
tial biological and clinical implications are compelling. In this
context, future studies will include sequencing of innate immu-
nity genes, including TLR3 and IRAK4, as well as genes that
directly or indirectly interact with these two markers. Such an
approach will allow us to identify, evaluate and validate biomark-
ers of innate immunity that may ultimately serve as potential
diagnostic, prognostic, and/or clinical management tools. Such
efforts are likely to provide further understanding of the con-
sequences of altered innate immunity on BrCa tumor progres-
sion. Functional studies are also needed to determine whether
genetic changes in the putative enhancer/silencer site of the IRAK4
gene and/or structural changes in IRAK4 due to the Ala248Thr
missense mutation alter the stability, activity, and/or protein–
protein interactions of this regulatory kinase. Future studies will
also address downstream effects of TLR3 and IRAK4 alterations
on immune/inflammatory responses and tumor behavior using
in vitro and in vivo models. Currently, our laboratory is devel-
oping and exploring the effects of strategically designed IRAK4
agonists and antagonists on the behavior of transformed breast
epithelia.
CONCLUSION
Our findings suggest that two mediators of innate immunity
signaling, TLR3 and IRAK4, may impact BrCa development
among African-American women. However, our results are pre-
liminary and require further evaluation in larger, ethnically diverse
populations.
ACKNOWLEDGMENTS
This research would not have been possible without the vol-
untary participation of women of African descent who were
willing to help us better understand the impact of the innate
immune system on BrCa. We appreciate the support of the
Emory Biomarker Service Center, Winship Cancer Institute for
Frontiers in Immunology | Molecular Innate Immunity October 2013 | Volume 4 | Article 338 | 8
Yeyeodu et al. IRAK4, TLR3, and BrCa risk
SNPStream allelic discrimination of innate immunity sequence
variants. This research was supported by the JGBCC Bucks for
Brains “Our Highest Potential” in Cancer Research Endowment
to LaCreis R. Kidd, Avon Foundation (Emory), Sindab Founda-
tion, Emory P60MD000525, UofL and NIEHS T32 ES011564, and
P20-MD000175 NIH NCMHD to K. Sean Kimbro.
REFERENCES
1. Schwartz GF, Hughes KS, Lynch HT,
Fabian CJ, Fentiman IS, Robson
ME, et al. Proceedings of the inter-
national consensus conference on
breast cancer risk, genetics, & risk
management, April, 2007. Cancer
(2008) 113:2627–37. doi:10.1002/
cncr.23903
2. Njiaju UO, Olopade OI. Genetic
determinants of breast cancer risk:
a review of current literature and
issues pertaining to clinical applica-
tion. Breast J (2012) 18:436–42. doi:
10.1111/j.1524-4741.2012.01274.x
3. Grivennikov SI,Greten FR,Karin M.
Immunity, inflammation, and can-
cer. Cell (2010) 140:883–99. doi:10.
1016/j.cell.2010.01.025
4. Hanahan D, Weinberg RA. Hall-
marks of cancer: the next genera-
tion. Cell (2011) 144:646–74. doi:
10.1016/j.cell.2011.02.013
5. Ishii KJ, Koyama S, Nakagawa A,
Coban C, Akira S. Host innate
immune receptors and beyond:
making sense of microbial infec-
tions. Cell Host Microbe (2008)
3:352–63. doi:10.1016/j.chom.2008.
05.003
6. Atkinson TJ. Toll-like receptors,
transduction-effector pathways,
and disease diversity: evidence of
an immunobiological paradigm
explaining all human illness? Int
Rev Immunol (2008) 27:255–81.
doi:10.1080/08830180801959072
7. Chen R, Alvero AB, Silasi DA, Stef-
fensen KD, Mor G. Cancers take
their Toll – the function and regula-
tion of Toll-like receptors in cancer
cells. Oncogene (2008) 27:225–33.
doi:10.1038/sj.onc.1210907
8. Rakoff-Nahoum S, Medzhitov R.
Toll-like receptors and cancer. Nat
Rev Cancer (2009) 9:57–63. doi:10.
1038/nrc2541
9. Kidd LR, Rogers EN, Yeyeodu ST,
Jones DZ, Kimbro KS. Contribu-
tion of toll-like receptor signaling
pathways to breast tumorigenesis
and treatment. Breast Cancer Tar-
gets Ther (2013) 2013:43–51. doi:10.
2147/BCTT.S29172
10. Sato Y, Goto Y, Narita N, Hoon
DSB. Cancer cell expressing Toll-
like receptors and the tumor
microenvironment. Cancer
Microenviron (2009) 2:S205–14.
doi:10.1007/s12307-009-0022-y
11. Demaria S, Pilones KA, Adams S.
Cross-talk of breast cancer cells with
the immune system. In: Gunduz
M, Gunduz E editors. Breast Can-
cer – Carcinogenesis, Cell Growth and
Signalling Pathways. Rijeka, Croatia:
InTech (2011). p. 457–82.
12. Xie W, Huang Y, Guo A, Wu W.
Bacteria peptidoglycan promoted
breast cancer cell invasiveness and
adhesiveness by targeting toll-like
receptor 2 in the cancer cells. PLoS
ONE (2010) 5:e10850. doi:10.1371/
journal.pone.0010850
13. Yang H, Zhou H, Feng P, Zhou X,
Wen H, Xie X, et al. Reduced expres-
sion of Toll-like receptor 4 inhibits
human breast cancer cells prolifer-
ation and inflammatory cytokines
secretion. J Exp Clin Cancer Res
(2010) 29:92–9. doi:10.1186/1756-
9966-29-92
14. Kang S-J, Tak J-H, Cho J-H,
Lee H-J, Jung Y-J. Stimulation
of the endosomal TLR pathway
enhances autophagy-induced cell
death in radiotherapy of breast
cancer. Genes Genomics (2010)
32:599–606. doi:10.1007/s13258-
010-0139-x
15. Cai Z, Sanchez A, Shi Z, Zhang
T, Liu M, Zhang D. Activation of
Toll-like receptor 5 on breast cancer
cells by flagellin suppresses cell
proliferation and tumor growth.
Cancer Res (2011) 71:2466–75.
doi:10.1158/0008-5472.CAN-10-
1993
16. Qiu J, Wang X, Guo X, Zhao C,
Wu X, Zhang Y. Toll-like receptor 9
agonist inhibits ERalpha-mediated
transactivation by activating NF-
kappaB in breast cancer cell lines.
Oncol Rep (2009) 22:935–41. doi:10.
3892/or_00000520
17. Lee JY, Park AK, Lee KM, Park SK,
Han S, Han W, et al. Candidate
gene approach evaluates association
between innate immunity genes and
breast cancer risk in Korean women.
Carcinogenesis (2009) 30:1528–31.
doi:10.1093/carcin/bgp084
18. Theodoropoulos GE, Saridakis V,
Karantanos T, Michalopoulos NV,
Zagouri F, Kontogianni P, et al.
Toll-like receptors gene polymor-
phisms may confer increased sus-
ceptibility to breast cancer develop-
ment. Breast (2012) 21:534–8. doi:
10.1016/j.breast.2012.04.001
19. Barnholtz-Sloan JS, Shetty PB,
Guan X, Nyante SJ, Luo J, Bren-
nan DJ, et al. FGFR2 and other
loci identified in genome-wide asso-
ciation studies are associated with
breast cancer in African-American
and younger women. Carcinogene-
sis (2010) 31:1417–23. doi:10.1093/
carcin/bgq128
20. Carey LA, Perou CM, Livasy CA,
Dressler LG, Cowan D, Conway
K, et al. Race, breast cancer sub-
types, and survival in the Car-
olina Breast Cancer Study. JAMA
(2006) 295:2492–502. doi:10.1001/
jama.295.21.2492
21. Stark A, Kleer CG, Martin
I, Awuah B, Nsiah-Asare A,
Takyi V, et al. African ances-
try and higher prevalence of
triple-negative breast cancer:
findings from an international
study. Cancer (2010) 116:4926–32.
doi:10.1002/cncr.25276
22. Hayanga AJ, Newman LA. Inves-
tigating the phenotypes and
genotypes of breast cancer in
women with African ancestry: the
need for more genetic epidemiol-
ogy. Surg Clin North Am (2007)
87:551–68. doi:10.1016/j.suc.2007.
01.003
23. Lund MJ, Butler EN, Bumpers HL,
Okoli J, Rizzo M, Hatchett N, et al.
High prevalence of triple-negative
tumors in an urban cancer center.
Cancer (2008) 113:608–15. doi:10.
1002/cncr.23569
24. Sherry ST, Ward MH, Kholodov M,
Baker J, Phan L, Smigielski EM, et
al. dbSNP: the NCBI database of
genetic variation. Nucleic Acids Res
(2001) 29:308–11. doi:10.1093/nar/
29.1.308
25. Shim JY. Transmembrane heli-
cal domain of the cannabinoid
CB1 receptor. Biophys J (2009)
96:3251–62. doi:10.1016/j.bpj.2008.
12.3934
26. Kuglstatter A, Villaseñor AG, Shaw
D, Lee SW, Tsing S, Niu L, et
al. Cutting Edge: IL-1 receptor-
associated kinase 4 structures reveal
novel features and multiple con-
formations. J Immunol (2007)
178:2641–5.
27. Essmann U, Perera L, Berkowitz
ML, Darden T, Lee H, Peder-
sen LH, et al. A smooth Particle
Mesh Ewald method. J Chem Phys
(1995) 103:8577–93. doi:10.1063/1.
470117
28. Kidd LR, Jones DZ, Rogers EN,
Beache S, Rudd JE, Ragin C, et al.
Chemokine ligand 5 (CCL5) and
chemokine receptor (CCR5) genetic
variants and prostate cancer risk
among men of African descent: a
case-control study. Hered Cancer
Clin Pract (2012) 10:16–27. doi:10.
1186/1897-4287-10-16
29. Wang L, Smith D, Bot S, Dellamary
L, Bloom A, Bot A. Noncoding RNA
danger motifs bridge innate and
adaptive immunity and are potent
adjuvants for vaccination. J Clin
Invest (2002) 110:1175–84. doi:10.
1172/JCI15536
30. Goutagny N, Estornes Y, Hasan
U, Lebecque S, Caux C. Target-
ing pattern recognition receptors
in cancer immunotherapy. Target
Oncol (2012) 7:29–54. doi:10.1007/
s11523-012-0213-1
31. He H, Genovese KJ, Swaggerty
CL, MacKinnon KM, Kogut MH.
Co-stimulation with TLR3 and
TLR21 ligands synergistically up-
regulates Th1-cytokine IFN-γ and
regulatory cytokine IL-10 expres-
sion in chicken monocytes. Dev
Comp Immunol (2012) 36:756–60.
doi:10.1016/j.dci.2011.11.006
32. Salaun B, Zitvogel L, Asselin-Paturel
C, Morel Y, Chemin K, Dubois C,
et al. TLR3 as a biomarker for the
therapeutic efficacy of double-
stranded RNA in breast cancer.
Cancer Res (2011) 71:1607–14.
doi:10.1158/0008-5472.CAN-10-
3490
33. Lacour J, Lacour F, Ducot B,
Spira A, Michelson M, Petit JY,
et al. Polyadenylic-polyuridylic acid
as adjuvant in the treatment
of operable breast cancer: recent
results. Eur J Surg Oncol (1988)
14:311–6.
34. Laplanche A, Alzieu L, Delozier
T, Berlie J, Veyret C, Pargeot P,
et al. Polyadenylic-polyuridylic acid
plus locoregionl radiotherapy ver-
sus chemotherapy with CMF in
operable breast cancer: a 14 year
follow-up analysis of a randomized
trial of the Federation Nationale des
Centres de Lutte Contre le Cancer
(FNCLCC). Breast Cancer Res Treat
(2000) 64:189–91. doi:10.1023/A:
1006498121628
35. Salaun B, Coste I, Rissoan MC,
Lebecque SJ, Renno T. TLR3 can
directly trigger apoptosis in human
cancer cells. J Immunol (2006)
176:4894–901.
36. Oshiumi H, Matsumoto M, Funami
K, Akazawa T, Seya T. TICAM-
1, an adaptor molecule that par-
ticipates in Toll-like receptor 3–
mediated interferon-β induction.
Nat Immunol (2003) 4:161–7. doi:
10.1038/ni886
www.frontiersin.org October 2013 | Volume 4 | Article 338 | 9
Yeyeodu et al. IRAK4, TLR3, and BrCa risk
37. Kagan JC, Su T, Horng T, Chow A,
Akira S, Medzhitov R. TRAM cou-
ples endocytosis of Toll-like recep-
tor 4 to the induction of interferon-
β. Nat Immunol (2008) 9:361–8.
doi:10.1038/ni1569
38. Sutherland AM, Walley KR, Nakada
TA, Sham AH, Wurfel MM, Rus-
sell JA. A nonsynonymous poly-
morphism of IRAK4 associated
with increased prevalence of gram-
positive infection and decreased
response to toll-like receptor lig-
ands. J Innate Immun (2011)
3:447–58. doi:10.1159/000323880
39. Scanlan MJ, Gordan JD, Williamson
B, Stockert E, Bander NH, Jongeneel
V, et al. Antigens recognized by
autologous antibody in patients
with renal-cell carcinoma. Int J
Cancer (1999) 83:456–64. doi:10.
1002/(SICI)1097-0215(19991112)
83:4<456::AID-IJC4>3.0.CO;2-5
40. Orazine CI, Hincapie M, Hancock
WS, Hattersley M, Hanke JH. A
proteomic analysis of the plasma
glycoproteins of a MCF-7 mouse
xenograft: a model system for the
detection of tumor markers. J Pro-
teome Res (2008) 7:1542–54. doi:10.
1021/pr7008516
41. McGettrick AF, O’Neill LA. Local-
isation and trafficking of Toll-
like receptors: an important mode
of regulation. Curr Opin Immunol
(2010) 22:20–7. doi:10.1016/j.coi.
2009.12.002
42. Suzuki N, Suzuki S, Yeh WC.
IRAK-4 as the central TIR signaling
mediator in innate immunity.
Trends Immunol (2002) 23:503–6.
doi:10.1016/S1471-4906(02)
02298-6
43. Lavender NA, Benford ML, Van-
Cleave TT, Brock GN, Kittles
RA, Moore JH, et al. Examina-
tion of polymorphic glutathione S-
transferase (GST) genes, tobacco
smoking and prostate cancer risk
among men of African descent:
a case-control study. BMC Can-
cer (2009) 9:397. doi:10.1186/1471-
2407-9-397
44. Benford ML, VanCleave TT, Laven-
der NA, Kittles RA, Kidd LR. 8q24
Sequence variants in relation to
prostate cancer risk among men
of African descent: a case-control
study. BMC Cancer (2010) 10:334.
doi:10.1186/1471-2407-10-334
45. VanCleave TT, Moore JH, Benford
ML,Brock GN,Kalbfleisch T,Baum-
gartner RN, et al. Interaction among
variant vascular endothelial growth
factor (VEGF) and its receptor in
relation to prostate cancer risk.
Prostate (2010) 70:341–52. doi:10.
1002/pros.21067
46. Kidd LC, Vancleave TT, Doll MA,
Srivastava DS, Thacker B, Komo-
lafe O, et al. No association between
variant N-acetyltransferase genes,
cigarette smoking and prostate can-
cer susceptibility among men of
African descent. Biomark Cancer
(2011) 2011:1–13. doi:10.4137/BIC.
S6111
47. Chang BL, Spangler E, Gallagher S,
Haiman CA, Henderson B, Isaacs
W, et al. Validation of genome-
wide prostate cancer associations
in men of African descent. Cancer
Epidemiol Biomarkers Prev (2011)
20:23–32. doi:10.1158/1055-9965.
EPI-10-0698
48. Calippe B, Douin-Echinard V,
Delpy L, Laffargue M, Lélu K,
Krust A, et al. 17Beta-estradiol
promotes TLR4-triggered proin-
flammatory mediator production
through direct estrogen receptor
alpha signaling in macrophages
in vivo. J Immunol (2010) 185:
1169–76. doi:10.4049/jimmunol.
0902383
49. Lesmeister M, Jorgenson R, Young
S, Misfeldt M. 17Beta-estradiol sup-
presses TLR3-induced cytokine and
chemokine production in endome-
trial epithelial cells. Reprod Biol
Endocrinol (2005) 3:74. doi:10.
1186/1477-7827-3-74
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 23 July 2013; accepted: 03 Octo-
ber 2013; published online: 29 October
2013.
Citation: Yeyeodu ST, Kidd LR, Oprea-
Ilies GM, Burns BG,VanCleave TT, Shim
J-Y and Kimbro KS (2013) IRAK4 and
TLR3 sequence variants may alter breast
cancer risk among African-American
women. Front. Immunol. 4:338. doi:
10.3389/fimmu.2013.00338
This article was submitted to Molecular
Innate Immunity, a section of the journal
Frontiers in Immunology.
Copyright © 2013 Yeyeodu, Kidd, Oprea-
Ilies, Burns, VanCleave, Shim and Kim-
bro. This is an open-access article distrib-
uted under the terms of the Creative Com-
mons Attribution License (CC BY). The
use, distribution or reproduction in other
forums is permitted, provided the origi-
nal author(s) or licensor are credited and
that the original publication in this jour-
nal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.
Frontiers in Immunology | Molecular Innate Immunity October 2013 | Volume 4 | Article 338 | 10
